UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C. 20549

                                FORM 10-QSB

      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 OR 15(d) OF THE
                       SECURITIES EXCHANGE ACT OF 1934

             For the quarterly period ended June 30, 2002
                                            --------------

                     Commission file number  000-29171

                                 MED GEN, INC.
       --------------------------------------------------------------
     [Exact name of small business issuer as specified in its charter]

        Nevada                                  65-0703559
------------------------                  -------------------------
(State of incorporation)               (IRS Employer Identification No.)


         7284 W. Palmetto Park Road, Suite 106, Boca Raton, FL 33433
         -----------------------------------------------------------
                    (Address of principal executive offices)

                                (561) 750-1100
                         ---------------------------
                         (Issuer's telephone number)

Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter
period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.

                  Yes [X]           No [ ]

Indicate the number of shares outstanding of each of the issuer's
classes of common stock, as of the latest practicable date.

Common Stock, Par Value $.001 per share

12,517,216 Shares outstanding as of August 9, 2002.

Transitional Small Business Disclosure Format (check one): Yes [ ] No  [X]




<PAGE>                                1




                                   INDEX
                                   -----

PART I.   FINANCIAL INFORMATION


Item 1.   Financial Statements

          Balance Sheet - June 30, 2002 (Unaudited)

          Statements of Operations - Three months and Nine months
ended
          June 30, 2002 and 2001 (Unaudited).

          Statements of Cash Flows - Nine months ended June 30, 2002
          and 2001 (Unaudited).

          Notes to Financial Statements (Unaudited).

Item 2.   Management's Discussion and Analysis of Financial
          Condition and Results of Operations.

PART II.  OTHER INFORMATION

Item 4.   Submission of Matters to a Vote of Securityholders

Item 5.   Other Information

Item 6.   Exhibits and Reports on Form 8-K


SIGNATURES




<PAGE>                                2





                    PART I - FINANCIAL INFORMATION

Item 1. Financial Statements




<PAGE>                                3




                                Med Gen, Inc.
                                Balance Sheet
                                June 30, 2002
                                 (Unaudited)

ASSETS

Current Assets
   Cash and cash equivalents                                $     264,521
   Accounts receivable                                            690,508
   Inventory                                                      230,808
   Officer advances                                                48,954
   Other current assets                                            16,500
                                                            -------------
      Total Current Assets                                      1,251,291
                                                            -------------

   Property and Equipment, net                                     97,338
                                                            -------------
Other Assets
   Deposits                                                        87,109
   Due from affiliates                                             74,134
   Other                                                           11,725
                                                            -------------

                                                            $   1,521,597
                                                            =============
LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities
   Accounts payable and accrued expenses                    $     438,028
   Notes payable - officers                                       100,000
   Notes payable                                                  435,000
   Convertible debentures                                         159,500
                                                            -------------
      Total Current Liabilities                                 1,132,528
                                                            -------------

Stockholders' Equity
   Preferred stock, $.001 par value, 5,000,000 shares
   authorized:
   Series A 8% cumulative, convertible, 1,500,000 shares
   authorized, 400,000 shares issued and outstanding              400,000
   Undesignated, 3,500,000 shares authorized                            -
   Common stock, $.001 par value, 20,000,000
   shares authorized, 12,417,216 shares
   issued and outstanding                                          12,417
   Paid in capital                                              4,000,133
   Accumulated (deficit)                                       (3,883,481)
                                                            -------------
                                                                  529,069
   Receivable for common stock                                   (130,000)
   Treasury stock, at cost 20,000 shares                          (10,000)
                                                            -------------
                                                                  389,069
                                                            -------------

                                                            $   1,521,597
                                                            =============


               See accompanying notes to financial statements.




<PAGE>                                4




                                Med Gen, Inc.
                           Statements of Operations
   For the Three Months and Nine Months Ended June 30, 2002 and 2001
                              (Unaudited)

<TABLE>
<CAPTION>

                                                         Three Months                  Nine Months
                                                    ------------------------    ------------------------
                                                       2002         2001            2002         2001
                                                    ----------    ----------    ----------    ----------
<S>                                                 <C>           <C>           <C>           <C>

Net Sales                                           $  919,587    $  845,026    $2,808,917    $1,612,357

Cost of Sales                                          348,806       336,965       993,320       555,101
                                                    ----------    ----------    ----------    ----------

                                                       570,781       508,061     1,815,597     1,057,256
                                                    ----------    ----------    ----------    ----------
Operating expenses:
  Non cash stock compensation                          284,875             -       518,867             -
  Selling, general and administrative expenses         698,468       448,849     1,828,528     1,060,978
                                                    ----------    ----------    ----------    ----------
                                                       983,343       448,849     2,347,395     1,060,978

(Loss) from operations                                (412,562)       59,212      (531,798)       (3,722)

Other (income) expense:
  Other (income) expenses                                    -         7,928       (22,884)       (2,810)
  Interest expense                                      15,725             -        46,314             -
  Non cash interest expense                                  -             -       210,000             -
                                                    ----------    ----------    ----------    ----------
                                                        15,725         7,928       233,430        (2,810)
                                                    ----------    ----------    ----------    ----------

Net income (loss)                                     (428,287)       51,284      (765,228)         (912)

Preferred dividends                                      7,000             -         8,842             -
                                                    ----------    ----------    ----------    ----------

Net income (loss) available to common shareholders  $ (435,287)   $   51,284    $ (774,070)   $     (912)
                                                    ==========    ==========    ==========    ==========
Per share information - basic and fully diluted:

 Weighted average shares outstanding                12,185,550     5,535,796    10,963,192     4,972,068
                                                    ==========    ==========    ==========    ==========

 Net income (loss) per share                            $(0.04)        $0.01        $(0.07)       $(0.00)
                                                    ==========    ==========    ==========    ==========

</TABLE>





              See accompanying notes to financial statements.




<PAGE>                                5




                                 Med Gen, Inc.
                          Statements of Cash Flows
             For the Nine Months Ended June 30, 2002 and 2001
                                (Unaudited)
<TABLE>
<CAPTION>

                                                    2002             2001
                                                 ----------       ----------
<S>                                              <C>              <C>

Cash flows from operating activities:
 Net cash (used in) operating activities         $ (533,714)      $ (391,371)
                                                 ----------       ----------
Cash flows from investing  activities:
 Net cash (used in) investing activities            (66,552)         (34,732)
                                                 ----------       ----------
Cash flows from financing activities:
 Net cash provided by financing activities          856,800          452,073
                                                 ----------       ----------

Net increase in cash                                256,534           25,970

Beginning - cash and cash equivalents                 7,987               27
                                                 ----------       ----------

Ending - cash and cash equivalents               $  264,521       $   25,997
                                                 ==========       ==========

</TABLE>

              See accompanying notes to financial statements.




<PAGE>                                6




                                MED GEN, INC.
                      NOTES TO FINANCIAL STATEMENTS
                              JUNE 30, 2002
                               (UNAUDITED)


(1)	Basis Of Presentation

The accompanying unaudited financial statements have been prepared in
accordance with generally accepted accounting principles  (GAAP) for
interim financial information and Item 310(b) of Regulation S-B. They do
not include all of the information and footnotes required by GAAP for
complete financial statements. In the opinion of management, all
adjustments (consisting only of normal recurring adjustments) considered
necessary for a fair presentation have been included.

The results of operations for the periods presented are not necessarily
indicative of the results to be expected for the full year.  For further
information, refer to the financial statements of the Company as of
September 30, 2001 and for the two years then ended, including notes
thereto included in the Company's Form 10-KSB.

(2)	Earnings Per Share

The Company calculates net income (loss) per share as required by
Statement of Financial Accounting Standards (SFAS) 128, "Earnings per
Share." Basic earnings (loss) per share is calculated by dividing net
income (loss) by the weighted average number of common shares
outstanding for the period. Diluted earnings (loss) per share is
calculated by dividing net income (loss) by the weighted average number
of common shares and dilutive common stock equivalents outstanding.
During periods when anti-dilutive commons stock equivalents are not
considered in the computation.

(3)	Inventory

Inventory is stated at the lower of cost, determined on a first in,
first out basis, or market value. Inventory consists principally of
finished goods and packaging materials.

(4)	Notes Payable

During October 2001 the Company refinanced certain loans into a $350,000
note payable due during January 2002 with interest at 7.5% per annum. As
additional consideration for the loan, the Company issued 1,500,000
shares of its common stock (see Note 6). During March 2002 the Company
refinanced this obligation into a $500,000 note payable. This note bears
interest at 8% per annum, requires interest payments of $3,333 per month
and is due on March 23, 2003. During the quarter ended June 30, 2002 the
Company repaid $65,000 of the principal balance to the lender.

(5)	Income Taxes

The Company accounts for income taxes under SFAS 109, "Accounting for
Income Taxes", which requires use of the liability method. SFAS 109
provides that deferred tax assets and liabilities are recorded based on
the differences between the tax bases of assets and liabilities and
their carrying amounts for financial reporting purposes, referred to as
temporary differences. Deferred tax assets and liabilities at the end of
each period are determined using the currently enacted tax rates applied
to taxable income in the periods in which the deferred tax assets and
liabilities are expected to be settled, or realized.




<PAGE>                                7




The Company's deferred tax asset of approximately $1,300,000 resulting
from net operating loss carryforwards aggregating approximately
$3,800,000 is fully offset by a valuation allowance. The Company has
recorded a valuation allowance to state its deferred tax assets at
estimated net realizable value due to the uncertainty related to
realization of these assets through future taxable income.

The provision for income taxes differs from the amount computed by
applying the statutory rate of 34% to income before income taxes due to
the effect of the net operating loss.

(6)	Stockholders' Equity

Common stock

During October 2001 the Company issued 735,000 shares of common stock
for consideration aggregating $147,000, pursuant to the exercise of
stock options by a consultant.

During October 2001 the Company issued 1,500,000 shares of common stock
as partial consideration for a loan (see Note 4). The Company charged
the fair value of these shares of $210,000 to interest expense during
the period ended June 30, 2002.

During January 2002 the Company issued 83,300 shares of common stock in
exchange for services. The Company charged the fair value of theses
shares of $19,992 to operations during the period ended June 30, 2002.

During January 2002 the Company agreed to issue 100,000 shares of common
stock for cash aggregating $10,000. The difference between the price
paid for the shares and their fair market value of $16,000 has been
charged to operations during the period. These shares were issued during
May 2002.

During the quarter ended March 31, 2002 the Company agreed to issue
800,000 shares of common stock to officers for services. The Company
charged the fair value of these shares of $198,000 to operations during
the period. These shares have not yet been issued.

During the period from October 1, 2001 to March 31, 2002 the Company
collected $202,000 of receivables for common stock.

During April 2002 the Company issued 1,000,000 shares of common stock to
officers pursuant to the exercise of stock options. The Company has
recorded the amount due from these officers of $130,000 as a receivable
for common stock.

During May 2002 the Company issued 1,000,000 shares of common stock to
officers and a consultant for services. The Company charged the fair
value of these shares of $301,000 to operations during the period. In
addition, during May 2002 the Company issued 40,000 shares of common
stock for cash aggregating $4,000. The difference between the price paid
for the shares and their fair market value of $4,000 has been charged to
operations during the period.

Preferred stock

During the period from February, to April 2002 the Company issued
400,000 shares of 8% cumulative convertible preferred stock for cash
aggregating $400,000. The preferred shares are convertible into common
shares of the Company at the option of the holder as follows:




<PAGE>                                8




  At any time after the Company's common stock price exceeds $3 per
share for a period of ten consecutive trading days the holder may
convert 50% of the value of the preferred shares held into common stock
at the rate of $.10 per common share (election to convert).

  The remaining 50% of the preferred shares will be converted into the
number of common shares of the Company determined by dividing the
balance of the value of the preferred shares held by the common stock
price at the time of the election to convert.

Notwithstanding the above, on the 25th monthly anniversary of the date of
the investments the preferred stock automatically converts into common
stock as follows:

  50% of the value of the preferred shares held converts into common
stock at the rate of $.10 per common share and the remaining 50% of the
value of the preferred shares held converts into the number of common
shares determined by dividing the balance of the value of the preferred
shares held by the common stock price at the 25th monthly anniversary.

The shares of common stock to be issued upon conversion are subject to
certain registration rights.

Any difference between the fair market value of the common shares and
the conversion price shall be recorded as an additional dividend on the
preferred stock at the time of the conversion.

Stock-based Compensation

During the period ended June 2002 the Company issued options to purchase
2,000,000 shares of common stock to officers and 50,000 shares of common
stock to non employees at $.23 per share.

SFAS 123 "Accounting for Stock-Based Compensation," requires the
Company to provide pro forma information regarding net income and
earnings per share as if compensation cost for the Company's stock
option plans had been determined in accordance with the fair value
based method prescribed in SFAS 123. The fair value of the option
grants is estimated on the date of grant utilizing the Black-Scholes
option pricing model. These results may not be representative of those
to be expected in future years.

Under the provisions of SFAS 123, the Company's net income (loss) and
earnings (loss) per share would have been reduced (increased) to the
pro forma amounts indicated below:

Net (loss)
            As reported                           $  (774,070)
            Pro forma                             $(1,054,070)


Basic and diluted (loss) per share

            As reported                           $(.07)
            Pro forma                             $(.10)




<PAGE>                                9




A summary of stock option activity is as follows:

<TABLE>
<CAPTION>

                                     Number        Weighted-       Weighted-
                                       of       average exercise     average
                                     shares          price         fair value
                                   ---------    ----------------   ----------
<S>                                <C>              <C>               <C>

  Balance at September 30, 2001    4,862,850
  Granted                          2,050,000        $.23              $.17
  Exercised                        1,000,000        $.13              $.13
  Forfeited                                -           -                 -
                                   ---------
  Balance at June 30, 2002         5,912,850
                                   =========
</TABLE>


(7)	Concentrations

During the period ended June 30, 2002 the Company derived 14%, 16% and
42% of its total sales from three major customers.

(8)	Convertible Debentures

On July 31, 2002 the company retired convertible debentures
aggregating $159,500 for cash.




<PAGE>                                10




Item 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
	  AND RESULTS OF OPERATIONS

RESULTS OF OPERATIONS
---------------------

Three months ended June 30, 2002
Compared with three months ended June 30, 2001
----------------------------------------------

For the 2002 third fiscal quarter ended June 30, 2002 ("Q-3"), Sales
increased 9% to $919,587 from $845,026 during 2001.  Gross Profit for
the third fiscal quarter was $570,781 versus $508,061 for the year ago
quarter, an increase of 11%.  Gross Profit Margins increased to 62% of
Sales in the quarter versus 60% for the year ago quarter.

Operating expenses increased to $698,468 for the quarter ended June
30, 2002 versus $448,849 during 2001.

Operating losses were $412,562 versus a year ago quarterly profit of
$59,212.  For the third fiscal quarter, the Company reported a loss of
$0.04 per share (versus a profit of $0.01 per share in the 2001
quarter).  The loss for the 2002 quarter reflects $284,875 in a non-
cash expense in connection with stock issued in lieu of cash
compensation.

Nine months ended June 30, 2002
Compared with nine months ended June 30, 2001
---------------------------------------------

For the first nine months of fiscal year 2002 ended June 30, 2002
("First Nine Months"), Sales increased 75% to $2,808,917 from
$1,612,357 in 2001.  Gross profit for the First Nine Months was
$1,815,597 versus $1,057,256 for the year ago first nine months, an
increase of 71%.  Gross Profit Margins decreased to 65% of Sales in
the First Nine Months versus 66% for the year ago first nine months.

Operating expenses exclusive of non-cash stock compensation increased
95% to $1,828,528 for the first nine months.  The increase in
operating expenses for the quarter and the nine months was related to
the following:

<TABLE>
<CAPTION>

                          2002            2001            2002            2001
                      Nine Months     Nine Months     Three Months     Three Months
                      -----------     -----------     ------------     ------------
<S>                   <C>             <C>             <C>              <C>

Advertising              $103,285        $ 25,264          $84,957          $ 9,811
Internet costs           $ 26,334        $  5,304          $13,448          $ 3,634
Insurance                $ 68,367        $ 53,011          $37,012          $ 8,960
Professional/Legal       $212,385        $ 68,978          $25,407          $57,580

</TABLE>

Operating losses were $531,798 for the First Nine Months of 2002
versus $3,722 for 2001.

For the fiscal First Nine Months, the Company reported a loss of $0.07
per share (versus a profit of $0.00 per share in the year earlier
period).  This per share loss reflects charging $518,867 in a non-cash
expense in connection with stock issued in lieu of cash compensation.




<PAGE>                                11





Forward-Looking Statements
--------------------------

This form 10-QSB contains certain forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
which are intended to be covered by the safe harbors created hereby.
Investors are cautioned that all forward-looking statements involve
risks and uncertainty, including without limitation, the Company's
future cash resources and liquidity.  Although the Company believes
that the assumptions underlying the forward-looking statements
contained herein are reasonable, any of the assumptions could be
inaccurate, and therefore, there can be no assurance that the forward-
looking statements included in this form 10-QSB will prove to be
accurate.  In light of the significant uncertainties inherent in the
forward-looking statements included herein, the inclusion of such
information should not be regarded as a representation by the Company
or any other person that the objectives and plans of the Company will
be achieved.

Item 3.  DEFAULTS UPON SENIOR SECURITIES
         -------------------------------

         Not Applicable

Item 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
         ---------------------------------------------------

         Not Applicable

Item 5.  OTHER INFORMATION
         -----------------

         Not Applicable

Item 6.  EXHIBITS AND REPORTS ON FORM 8-K
         --------------------------------

        (a)     There are no exhibits required to be filed for the period
                covered by this Report.

        (b)     There were no reports filed on Form 8-K for the period
                covered by this Report.



SIGNATURES

In accordance with the requirements of the Exchange Act, the
registrant caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.


                                             Med Gen, Inc.
                                             (Registrant)


Date: August 9, 2002
                                             By:__/s/Paul B. Kravitz_____
						Paul B. Kravitz
						Chief Executive Officer



<PAGE>                                12